ETOHOPE FILM-COATED TABLET 90 MG

GLENMARK PHARMACEUTICALS LIMITED (INDIA)🇸🇬 Health Sciences Authority

Approval Date: Jun 20, 2022
Approval ID: 72d08689674d7d8b
Company: GLENMARK PHARMACEUTICALS LIMITED (INDIA)
Type: Therapeutic

Approval Details

Approval Id: 72d08689674d7d8b
Drug Name: ETOHOPE FILM-COATED TABLET 90 MG
Product Name: ETOHOPE FILM-COATED TABLET 90 MG
Approval Number: SIN16516P
Approval Date: 2022-06-20
Registrant: GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.
Licence Holder: GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: Posology and method of administration Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re - evaluated periodically, especially in patients with osteoarthritis. Osteoarthritis In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Rheumatoid arthritis The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Ankylosing spondylitis The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. Acute pain conditions For acute pain conditions, etoricoxib should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. The recommended dose is 90mg or 120mg once daily. Acute gouty arthritis The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days. Etoricoxib 120 mg should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. Postoperative dental surgery pain The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to Etoricoxib Tablet during the three day treatment period. Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60 mg daily. The dose for RA and ankylosing spondylitis should not exceed 90 mg daily. The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment. The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days. Special populations Elderly patients No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients. Patients with hepatic impairment In patients with mild hepatic insufficiency (Child-Pugh score 5–6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic insufficiency (Child-Pugh score 7–9) the recommended dose of 60 mg every other day should not be exceeded. Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score ≥10); therefore, its use is contra-indicated in these patients. Patients with renal impairment No dosage adjustment is necessary for patients with creatinine clearance ≥30 ml/min. The use of etoricoxib in patients with creatinine clearance <30 ml/min is contra-indicated. Paediatric population Etoricoxib is contra-indicated in children and adolescents under 16 years of age. Method of administration Etoricoxib Tablet is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when Etoricoxib Tablet is administered without food. This should be considered when rapid symptomatic relief is needed.
Route Of Administration: ORAL
Indication Info: Therapeutic indications Etoricoxib Tablet is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. Etoricoxib Tablet is indicated in adults and adolescents 16 years of age and older for the short-term treatment of acute pain associated with minor dental surgery. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks, taking into consideration other available therapeutic options (see sections contraindications, special warnings and precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications: Contraindications <ul> <li>Hypersensitivity to the active substance or to any of the excipients of this medicinal product.</li> <li>Active peptic ulceration or active gastro-intestinal (GI)bleeding.</li> <li>Patients who, after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions.</li> <li>Pregnancy and lactation.</li> <li>Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score≥10).</li> <li>Estimated renal creatinine clearance <30 ml/min. <ul> <li>Children and adolescents under 16 years of age.</li> <li>Inflammatory bowel disease.</li> <li>Congestive heart failure (NYHA II–IV).</li> <li>Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled.</li> </ul></li> <li>Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty).</li> </ul>
Atc Code: M01AH05
Atc Item Name: etoricoxib
Pharma Manufacturer Name: GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.
Company Detail Path: /organization/glenmark-pharmaceuticals-singapore-pte-ltd

Active Ingredients

Etoricoxib

90 mg

Etoricoxib

90 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 20, 2022

Approval ID

72d08689674d7d8b

Type

Therapeutic

Back to HSA Approvals